Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Viatris Inc
(NQ:
VTRS
)
11.70
-0.02 (-0.17%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Viatris Inc
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022
May 10, 2022
Upgrades
Via
Benzinga
Expert Ratings for Viatris
May 10, 2022
Analysts have provided the following ratings for Viatris (NASDAQ:VTRS) within the last quarter:
Via
Benzinga
3 Top S&P 500 Stock Market Gainers Today
May 09, 2022
Hard-hit stocks led S&P 500 winners. Commodity stocks were the big losers.
Via
Investor's Business Daily
Viatris Posts Q1 Profit Despite 5% Dip In Sales, Reiterates FY22 Guidance Above Consensus
May 09, 2022
Via
Benzinga
Recap: Viatris Q1 Earnings
May 09, 2022
Viatris (NASDAQ:VTRS) reported its Q1 earnings results on Monday, May 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Viatris' Mylan Recalls One Batch Of Insulin Glargine Due To Missing Label
April 13, 2022
Mylan Pharmaceuticals Inc, a Viatris Inc (NASDAQ: VTRS) company, is
Via
Benzinga
27 Recession-Resistant Stocks To Look At Now
May 09, 2022
When we enter a period of economic uncertainty, the phrase "recession-proof stocks" is tossed about, but really the only certainty is that recession-proof stocks do not...
Via
Benzinga
Pfizer: What Comes After the Covid-19 Fire?
April 21, 2022
Success with Pfizer's Covid-19 vaccine maintains the PFE stock status as a dividend aristocrat, but don't expect miracles.
Via
InvestorPlace
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
April 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal
Via
Benzinga
High Dividend 50: Viatris
March 25, 2022
Viatris is currently offering an above-average dividend yield of 4.4%. The company has posted GAAP losses in each of the last two years but its payout ratio is only 13% using adjusted EPS.
Via
Talk Markets
Viatris: Q4 Earnings Insights
February 28, 2022
Viatris (NASDAQ:VTRS) reported its Q4 earnings results on Monday, February 28, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
Earnings Scheduled For February 28, 2022
February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...
Via
Benzinga
Earnings Scheduled For May 9, 2022
May 09, 2022
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.
Via
Benzinga
Biogen’s Aduhelm Crashes the Biotech Sector
April 13, 2022
Aduhelm's quick approval and high price have set off pushback on the whole FDA and Medicare drug process which is not good for BIIB stock.
Via
InvestorPlace
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
April 03, 2022
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...
Via
Benzinga
7 Cheap Stocks to Buy Now if You Have $100 to Spend
March 22, 2022
The S&P 500 is off to a forgettable start this year, but that creates multiple buying opportunities if you're looking for cheap stocks.
Via
InvestorPlace
35 Generic Drugmakers Sign To Manufacture Low-Cost Version Of Pfizer's COVID Pill
March 17, 2022
Via
Benzinga
7 Drug Stocks to Consider After the Viatris Plunge
March 10, 2022
As Viatris and other generic drug makers plunge, what should you buy instead? Consider these seven well-known drug stocks, all of which are good value in what's still a pricey market.
Via
InvestorPlace
AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar
March 09, 2022
Alvotech Holdings S.A. has entered into a settlement agreement with AbbVie Inc (NYSE: ABBV), allowing Alvotech to market AVT02 (100 mg/mL), its high-...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022
March 01, 2022
Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,...
Via
Benzinga
Viatris's Return On Capital Employed Overview
March 01, 2022
Benzinga Pro data, Viatris (NASDAQ:VTRS) reported Q4 sales of $4.34 billion. Earnings fell to a loss of $263.80 million, resulting in a 184.69% decrease from last quarter....
Via
Benzinga
67 Biggest Movers From Yesterday
March 01, 2022
Gainers Mullen Automotive, Inc. (NASDAQ: MULN) climbed 145.6% to close at $1.69 on Monday after the company reported progress on solid-state polymer battery pack...
Via
Benzinga
Why Viatris Shares Are Trading Lower Today
February 28, 2022
Viatris Inc (NASDAQ: VTRS) is trading lower Monday after the company reported worse-than-expected top-line results for the fourth quarter and issued guidance...
Via
Benzinga
Viatris To Pay $264M As EpiPen Antitrust Litigation Settlement: Reuters
February 28, 2022
Viatris Inc (NASDAQ: VTRS), previously known as Mylan, has agreed to pay $264 million to resolve a class-action lawsuit alleging it engaged in a scheme to delay...
Via
Benzinga
42 Stocks Moving In Monday's Mid-Day Session
February 28, 2022
Gainers Mullen Automotive, Inc. (NASDAQ: MULN) jumped 74.4% to $1.20 after the company reported progress on solid-state polymer battery pack development. Renewable Energy Group...
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
February 28, 2022
On Monday morning, 66 companies achieved new lows for the year. Noteable 52-Week Lows: Gilead Sciences (NASDAQ:GILD) was the largest firm on a market cap basis to set a...
Via
Benzinga
Mid-Morning Market Update: Markets Open Lower Amid Ongoing Russia-Ukraine Conflict
February 28, 2022
U.S. stocks opened on a downbeat note this morning, amid the ongoing Russia-Ukraine conflict, which has led to increased US sanctions on Russia. Following the market opening...
Via
Benzinga
India-Based Biocon To Buy Viatris' Biosimilars Assets In $3.3B Deal
February 28, 2022
Biocon Biologics Ltd has agreed to acquire Viatris Inc's (NASDAQ: VTRS) biosimilars assets for up to $3.335 billion in stock and cash. The deal value...
Via
Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...
Via
Benzinga
A Bullish Sign Appears On Viatris's Chart
February 16, 2022
If history is any guide, there may be good fortune ahead for shares of Viatris (NASDAQ:VTRS). A so-called "golden cross" has formed on its chart and, not surprisingly, this could...
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.